Free Trial

RUA Life Sciences (RUA) Competitors

RUA Life Sciences logo
GBX 11.12 -0.63 (-5.32%)
As of 11:23 AM Eastern

RUA vs. POLX, IHC, AVO, MHC, SUN, BELL, DEMG, NIOX, SN, and MXCT

Should you be buying RUA Life Sciences stock or one of its competitors? The main competitors of RUA Life Sciences include Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), MyHealthChecked (MHC), Surgical Innovations Group (SUN), Belluscura (BELL), Deltex Medical Group (DEMG), NIOX Group (NIOX), Smith & Nephew (SN), and MaxCyte (MXCT). These companies are all part of the "medical devices" industry.

RUA Life Sciences vs.

RUA Life Sciences (LON:RUA) and Polarean Imaging (LON:POLX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.

RUA Life Sciences has a net margin of -65.72% compared to Polarean Imaging's net margin of -1,333.97%. RUA Life Sciences' return on equity of -26.38% beat Polarean Imaging's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-65.72% -26.38% -17.50%
Polarean Imaging -1,333.97%-86.11%-32.28%

26.0% of RUA Life Sciences shares are held by institutional investors. Comparatively, 12.1% of Polarean Imaging shares are held by institutional investors. 51.3% of RUA Life Sciences shares are held by insiders. Comparatively, 39.3% of Polarean Imaging shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Polarean Imaging received 23 more outperform votes than RUA Life Sciences when rated by MarketBeat users. Likewise, 67.65% of users gave Polarean Imaging an outperform vote while only 0.00% of users gave RUA Life Sciences an outperform vote.

CompanyUnderperformOutperform
RUA Life SciencesOutperform Votes
No Votes
Underperform Votes
6
100.00%
Polarean ImagingOutperform Votes
23
67.65%
Underperform Votes
11
32.35%

RUA Life Sciences has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Polarean Imaging has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.

RUA Life Sciences has higher earnings, but lower revenue than Polarean Imaging. RUA Life Sciences is trading at a lower price-to-earnings ratio than Polarean Imaging, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.05M1.70-£2.66M-£4.29-2.59
Polarean Imaging£5.21M2.82-£69.44M-£3.89-0.26

In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Polarean Imaging'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
Polarean Imaging Neutral

Summary

RUA Life Sciences beats Polarean Imaging on 7 of the 13 factors compared between the two stocks.

Remove Ads
Get RUA Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RUA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RUA vs. The Competition

MetricRUA Life SciencesMedical Devices IndustryMedical SectorLON Exchange
Market Cap£6.90M£3.51B£5.55B£2.52B
Dividend Yield1.44%2.44%5.35%4.90%
P/E Ratio-2.5978.2322.94134.65
Price / Sales1.70125.95361.58261,054.86
Price / Cash2.4015.9938.1627.90
Price / Book0.523.686.494.45
Net Income-£2.66M£126.02M£3.21B£5.77B
7 Day Performance-3.85%-4.12%-6.28%-1.85%
1 Month Performance-14.09%-7.80%-0.55%-2.65%
1 Year Performance27.14%-12.56%6.18%103.94%

RUA Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RUA
RUA Life Sciences
N/AGBX 11.13
-5.3%
N/A+37.9%£6.90M£4.05M-2.5948
POLX
Polarean Imaging
N/AGBX 1.12
-0.9%
N/A-74.8%£16.37M£5.21M-0.2928Gap Down
IHC
Inspiration Healthcare Group
N/AGBX 16.60
-0.9%
N/A-40.8%£14.38M£42.87M-1.14224Positive News
Gap Down
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/A-25.003,900Gap Down
MHC
MyHealthChecked
N/AGBX 15.40
+1.0%
N/A+12.8%£8.01M£9.43M-7.6816Gap Down
SUN
Surgical Innovations Group
N/AGBX 0.57
+2.7%
N/A+13.0%£5.27M£12.54M-21.1180News Coverage
Gap Up
BELL
Belluscura
N/AGBX 1.50
-4.8%
N/A-83.2%£3.78M£2.87M-0.1624Gap Down
High Trading Volume
DEMG
Deltex Medical Group
N/AN/AN/AN/A£187,000.00£1.76M-0.1537Gap Up
High Trading Volume
NIOX
NIOX Group
N/AGBX 74.12
+1.3%
N/A+17.2%£30.44B£3.53B3,058.8092Earnings Report
Insider Trade
News Coverage
SN
Smith & Nephew
3.9279 of 5 stars
GBX 1,080
-0.5%
GBX 4,607.50
+326.6%
N/A£11.84B£7.08B38.8818,452High Trading Volume
MXCT
MaxCyte
N/AGBX 236.80
-1.3%
N/A-36.6%£312.59M£57.52M-8.6880Gap Down
Remove Ads

Related Companies and Tools


This page (LON:RUA) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners